For the last three decades, the Middle East & African countries have witnessed some critical social and economic transformations, which involve rapid economic growth and urbanization, along with reduced infant mortality and increased life expectancy.
Meanwhile, a few countries in the region have seen a decreased economy, due to political tension, along with other social factors, such as terrorism.
In the Middle East & Africa, approximately 35.5 million people live with diabetes. Middle Eastern countries have a high diabetes prevalence.
For instance, the percentages of type 2 diabetes in a few important countries are as follows: Saudi Arabia 24%, Kuwait 23%, Bahrain 22%, Qatar 20%, and UAE 19%.
It is estimated that only USD 17 billion was spent on diabetes, despite high prevalence in the region. Growth in the number of middle-class households, as well as increasing per capita income in these countries, will result in better spending power in general, thereby helping to drive the market during the forecast period (2019-2024).
Along with this, a few important factors, such as advanced healthcare infrastructure, technological advancement, and availability of skilled medical professionals, are likely to play paradigm shifting roles in the overall growth of this market.
The Middle East & Africa region suffers from a high burden of diabetes, and its adverse health and economic consequences. The disease should be viewed as a serious threat, not just from public health, but also from a development perspective. With risk factors, such as increasing obesity, and progressively aging populations, the diabetes epidemic is growing, especially in low- and middle-income countries in the region. It is one of the most common chronic diseases in Saudi Arabia, followed by Kuwait.
Scope of the Report
The market is segmented by drug (Exenatide, Liraglutide, Dulaglutide, Lixisenatide), by brand (Byetta, Bydureon, Victoza, Trulicity, Lyxumia), and by geography.
Key Market Trends - Rising Prevalence of Diabetes
As per a WHO report, the global prevalence of diabetes, among people of over 18 years, has accelerated from about 4.7%, in 1980, to over 8.5%, in 2014.
Diabetes prevalence has been rising rapidly in middle- and low-income countries. In 2015, about 1.6 million deaths were directly associated with diabetes, which was around 2.2 million in 2012.
Almost half of all deaths attributable to high blood glucose occur before the age of 70. WHO projects that diabetes is likely to be the seventh leading cause of death by 2030.
Statistics prove that one in ten individuals in the country has diabetes and a rise in this trend is expected to take the situation to one in three, by 2050 (according to the Center for Disease Control and Prevention).
The growing prevalence of diabetes is the primary driver for the global diabetes care drugs market. Additionally, raising awareness regarding diabetes care, growing prevalence of obesity, and technological advancements are further driving the market.
Saudi Arabia to Lead the GLP-1 Market
The GLP-1 market is expected to witness a high CAGR, of 13.4%, over the forecast period. Saudi Arabia is expected to hold the highest market share in the Middle East & Africa GLP-1 agonist market.
Victoza holds the highest market share in the region and the same trend is seen in Saudi Arabia. Trulicity is expected to have the highest growth during the forecast period (2019-2024)
The Saudi Arabian market is expected to see robust growth during the forecast period (2019-2024), due to the high number of R&D-related investments in the market. Some of these pipeline products are two of Sanofi’s GLP-1s, efpeglenatide and SAR425899, which are expected to launch in 2020 and 2021, respectively.
The global GLP-1 market is consolidated, with four major manufacturers holding their presence in all regions.
The market for GLP-1 agonist drugs includes Victoza, Trulicity, Byetta, Bydureon, and Lyxumia. The market is expected to grow significantly, during the forecast period, due mainly to Trulicity and Ozempic.
Oral Semaglutide, which is in phase 3 of its clinical trials, is expected to launch by 2020. The product has shown better results than Januvia in studies.
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Drug
18.104.22.168 Byetta (Value and Volume 2012-2024)
22.214.171.124 Bydureon (Value and Volume 2012-2024)
126.96.36.199 Victoza (Value and Volume 2012-2024)
188.8.131.52 Lyxumia (Value and Volume 2012-2024)
184.108.40.206 Trulicity (Value and Volume 2012-2024)
5.2.1 Middle East & Africa
220.127.116.11 Saudi Arabia (Value and Volume 2012-2024)
18.104.22.168.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
22.214.171.124.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
126.96.36.199 Egypt (Value and Volume 2012-2024)
188.8.131.52.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
184.108.40.206.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
220.127.116.11 Iran (Value and Volume 2012-2024)
18.104.22.168.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
22.214.171.124.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
126.96.36.199 South Africa (Value and Volume 2012-2024)
188.8.131.52.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
184.108.40.206.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
220.127.116.11 Oman (Value and Volume 2012-2024)
18.104.22.168.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
22.214.171.124.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
126.96.36.199 Rest of Middle East & Africa (Value and Volume 2012-2024)
188.8.131.52.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
184.108.40.206.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
6 MARKET INDICATORS
6.1 Type-1 Diabetes Population (2012-2024)
6.2 Type-2 Diabetes Population (2012-2024)
7 COMPETITIVE LANDSCAPE
7.1 COMPANY PROFILES
7.1.1 Novo Nordisk
7.1.3 Eli Lilly
7.2 MARKET SHARE ANALYSIS
7.2.1 Novo Nordisk
7.2.3 Eli Lilly
8 MARKET OPPORTUNITIES AND FUTURE TRENDS